Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

NMN/NR and Cannabis: Full Interaction Profile, Risks, and Clinical Guidance

By
Published Updated Last reviewed
11 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Evidence on the pair / no human study of NMN or NR with cannabis was found [1]
  • What NMN does / NMN 250 to 900 mg per day raised blood NAD+ in trials [2][3]
  • Trial safety record / no obvious adverse effects, safety issues or severe adverse events reported in trials of 4 to 12 weeks [2][3][4]
  • Long-term data / lacking beyond about 12 weeks [1]
  • Regulatory status / sold as dietary supplements; neither is FDA-approved [5]

What the NMN and NR Trials Actually Tested

The trials were short, with doses and populations that varied by study.

  • NMN 250 mg/day for 12 weeks in 30 healthy adults: no abnormalities on physiological or laboratory tests and no obvious adverse effects; whole-blood NAD+ rose [2].
  • NMN 300, 600 or 900 mg/day for 60 days in 80 middle-aged adults: blood NAD rose in all NMN groups; no safety issues on adverse-event, laboratory or clinical monitoring [3].
  • NMN 1,250 mg once daily for up to 4 weeks in 31 adults aged 20 to 65: no severe adverse events and no changes beyond normal variation in hematology, biochemistry, urine or body composition [4].
  • NR 500 mg twice daily in a 6-week crossover trial in adults aged 55 to 79: well tolerated, with 14 mild adverse events in 7 participants (nausea, flushing, leg cramps, bruising) and no serious events [6].
  • NR 1,000 mg twice daily for 12 weeks in 40 sedentary obese men: no serious adverse events [7].

A 2023 review of NAD+-boosting supplements in humans noted that dosing regimens and study durations vary widely and that small sample sizes limit what the outcomes can tell us [1].

Is There Any Signal Linking Cannabis to NAD+?

One hypothesis-level observation: a 2026 narrative review of transcriptome-wide association data proposed that cannabis use disorder profiles show stronger involvement of selected NAD and sirtuin stress-response branches, while its author described the work as hypothesis-generating because the evidence comes from predicted gene expression rather than measured patient expression [8]. That is not a measurement of NAD+ in anyone using cannabis.

Regulatory Status of Each Product

NMN and NR are sold in the US as oral dietary supplements. Neither is an FDA-approved drug, and no NAD+ precursor is approved by FDA to treat aging or any disease [5].

Trade press reported that in late 2022 FDA told two ingredient makers that NMN could not be marketed as a supplement, because it had been authorized for investigation as a new drug before it was sold as a supplement [10]. Law-firm and trade reports of FDA's response to a citizen petition, dated 2025-09-29, say FDA reversed that position and concluded NMN is not excluded from the dietary supplement definition. NMN remains a new dietary ingredient, so a maker must submit an NDI notification or rely on a prior notification covering that supplier's ingredient before selling it [5]. For NR, FDA said in 2016 that it had no questions about ChromaDex's own GRAS conclusion, without making its own determination [11].

What Is Unknown

Long-term safety data beyond about 12 weeks are lacking, and the trials were small (12 to 140 participants) [1]. A higher cancer risk with chronic NAD+ boosting has been raised as a theoretical concern, but no human data were identified [1]. Pregnancy, breastfeeding, children, and people with cancer, kidney disease or liver disease were not studied in the cited trials, so safety in these groups is unknown [1].

Frequently asked questions

Is it safe to take NMN or NR with cannabis?
It has not been studied. Short trials of NMN alone reported no obvious adverse effects, no safety issues, or no severe adverse events, depending on the trial, but no human interaction studies of NMN or NR with any drug were found [2][3][4][1].
Does NMN or NR change how quickly cannabis is metabolized?
No human drug-interaction study of NMN or NR (enzyme, transporter or other) was found, so this is unmeasured [1].
Is NMN legal to buy as a supplement?
Reports of FDA's petition response dated 2025-09-29 say FDA concluded NMN is not excluded from the dietary supplement definition. Makers must still submit a new dietary ingredient notification or rely on a prior one covering their ingredient [5].

References

  1. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. J Gerontol A Biol Sci Med Sci. 2023;78(12):2435-2448. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions
  2. Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9:868640. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects
  3. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
  4. Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12(1):14442. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women
  5. Official web page. Official web page
  6. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
  7. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects
  8. Cheung N. Cross-Disorder Pruning-Plasticity-Aging Architecture in Substance Use Disorders and Anxiety: Transcriptome-Wide Association Insights and Mechanistic Synthesis. Cureus. 2026;18(6):e110806. Cross-Disorder Pruning-Plasticity-Aging Architecture in Substance Use Disorders and Anxiety: Transcriptome-Wide Association Insights and Mechanistic Synthesis
  9. Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism
  10. Official web page. Official web page
  11. Agency Response Letter GRAS Notice No. GRN 000635 | FDA. Agency Response Letter GRAS Notice No. GRN 000635 | FDA
Evidence overview for NMN/NR and Cannabis: Full Interaction Profile, Risks, and Clinical Guidance